KiOmedine® CM-Chitosan is Effective for Treating Advanced Symptomatic Knee Osteoarthritis up to Six Months Following a Single Intra-Articular Injection: A Post Hoc Analysis of Aproove Clinical Study

Background: Symptomatic knee osteoarthritis (OA) is typically treated with hyaluronan-based intra-articular injections. Advanced OA patients are often unresponsive to hyaluronan. KiOmedine ® Carboxymethyl-Chitosan (CM-Chitosan), a novel fluid implant, was safe and effective for treating symptomatic OA. Objective: The objective of this study describe the efficacy single injection CM-Chitosan in advanced Methods: Patients enrolled APROOVE trial were identified: subgroup-1, BMI >30 kg/m 2 and/or Kellgren Lawrence (KL) grade III (n=39), subgroup-2, KL-grade (n=8). Within-group analyses performed using WOMAC scores OMERACT-OARSI responder criteria at 3 6 months. Results: In both subgroups, significant improvements all observed months (p<0.001 comparisons). A high rate subgroup-1 (63.2% 65.8%) subgroup-2 (57.1% 62.5%). Conclusion: This post hoc analysis showed that could be an therapeutic option Clinical registration number: Clinicaltrial.gov identifier: Net30679208.